Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8740)	2/16/1999 9:22:00 AM
From: Arthur Radley	Respond to of 17367

Another teenager died here in Houston with meningo. Hurry up! Hurry up!

To: Robert K. who wrote (8740)	2/16/1999 12:27:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Glaxo/Fungi informative, IMO. glaxowellcome.co.uk

To: Robert K. who wrote (8740)	2/17/1999 10:13:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Herman Waldman Phd from U.K. on Xoma Scientific Advisory Board. Search produced many references. One is posted below. molbiol.ox.ac.uk ALSO: Tel: 01865 275502 (Department) herman.waldmann@lincoln.ox.ac.uk Professor Herman Waldmann (FRCPath, MRCP, FRS) was educated in Cambridge and the London Hospital. He is (since 1994) the Head of the Sir William Dunn School of Pathology. His research interests lie in the field of Immunological Tolerance where he is attempting to understand why the immune system can react to foreign microbes and yet does not usually react to self. If one could reprogramme the immune system to become tolerant to foreign tissue grafts or to any substance it was reacting to, then this would obviate the need for long-term treatment with the immunosuppressive drugs. His non-research interests are in family, food, friends and paradise-style travel. NOTE "Paradise style travel" Hope that's not at Xoma's expense!